Cargando…

Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis

BACKGROUND: Rifaximin is an oral antimicrobial drug with a broad-spectrum effect. It locally regulates the function and structure of intestinal bacteria and decreases intestinal endotoxemia. We aimed to investigate the preventive role of rifaximin in recurrent episodes of hepatic encephalopathy in c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elmoursi, Ahmed, Abdelsattar, Ahmed Taha, Khalil, Farag, Shabana, Hosam, Abdel-Moety Zedan, Hendawy, Mohamed El Mancy, Ismail, Ramadan, Ibrahim Ghounim, Mostafa, Sadek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish Society of Gastroenterology 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441098/ https://www.ncbi.nlm.nih.gov/pubmed/37051626 http://dx.doi.org/10.5152/tjg.2023.22575

Ejemplares similares

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Hypokalemia as a responsible factor related with the severity of hepatic encephalopathy: a wide multination cross-sectional study
por: Ullah, Himayat, et al.
Publicado: (2023)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Prevalence and Clinical Significance of Subclinical Hypothyroidism in Diabetic Peripheral Neuropathy
por: Allam, Mahmoud A, et al.
Publicado: (2021)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
por: Cheng, Junxiong, et al.
Publicado: (2021)

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
por: Tan, Wei, et al.
Publicado: (2022)

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
por: Bajaj, J S, et al.
Publicado: (2015)

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
por: Mangas-Losada, Alba, et al.
Publicado: (2019)

Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy
por: Chautant, Fiona, et al.
Publicado: (2020)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
por: Fu, Jian, et al.
Publicado: (2022)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
por: Yukawa‐Muto, Yoshimi, et al.
Publicado: (2022)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases
por: El-Senosy, Fatma M., et al.
Publicado: (2022)

Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
por: Pawar, Vinay B., et al.
Publicado: (2019)

Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin
por: Sarwar, Shahid, et al.
Publicado: (2019)

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy
por: Oey, Rosalie C., et al.
Publicado: (2019)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
por: Yu, Xiao, et al.
Publicado: (2022)

Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α
por: Deltenre, Pierre, et al.
Publicado: (2021)

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy
por: Parisse, Simona, et al.
Publicado: (2023)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
por: Torre, Aldo, et al.
Publicado: (2023)

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
por: Roggeri, Daniela Paola, et al.
Publicado: (2017)

Assessment of integrated specialty pharmacy services as a medication optimization strategy for rifaximin in hepatic encephalopathy patients
por: Mac, Elezabeth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7cr8t962crt171f445celc0gs0